Import from '@/components/mdx'

MOTS-c Before Surgery: How Long to Hold, Why It Matters, and What Changes for Women

What Is MOTS-c and Why Are Women Using It?

MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded entirely within the mitochondrial genome, specifically the 12S rRNA gene. Lee et al. First described it in 2015 in Cell Metabolism, demonstrating that it activates AMPK signaling, improves insulin sensitivity, and reduces adiposity in mouse models fed a high-fat diet. That single paper launched years of off-label clinical interest.

For women, the draw is specific. Conditions like polycystic ovary syndrome (PCOS), perimenopausal insulin resistance, and post-menopausal metabolic shift all involve mitochondrial dysfunction and impaired glucose handling. MOTS-c targets exactly those pathways. Women with PCOS, which affects roughly 6-12% of reproductive-age women in the United States, are among the most enthusiastic early adopters, often pairing MOTS-c with inositol or metformin under the supervision of a reproductive endocrinologist.

How MOTS-c Works at the Cellular Level

MOTS-c travels from the mitochondria into the cytoplasm and then into the nucleus, where it activates the AMPK/SIRT1 axis and suppresses the folate cycle to limit one-carbon metabolism. The 2015 Lee et al. Data showed that exogenous MOTS-c injected intraperitoneally in obese mice reduced fasting glucose, improved oral glucose tolerance, and increased skeletal muscle fatty-acid oxidation. These effects occurred without changes in food intake, which distinguished MOTS-c from GLP-1 receptor agonists mechanistically.

In the nucleus, MOTS-c also appears to regulate antioxidant response elements, which is why researchers are now exploring it in the context of ovarian aging. Mitochondrial density and function decline in granulosa cells as women approach perimenopause. Whether exogenous MOTS-c can reverse that decline is an open question; a 2023 pilot study in Aging hinted at mitochondrial biogenesis effects in older human skeletal muscle, but the sample was small and female-specific subgroup data were not reported separately.

The Evidence Gap That Women Deserve to Hear

Women have been systematically under-represented in peptide and metabolic research trials. The foundational Lee et al. 2015 mouse work used both male and female mice, but most downstream animal mechanistic work has defaulted to male rodents. The NIH policy requiring sex as a biological variable in preclinical research only began to be enforced from 2016 onward, meaning a significant portion of the MOTS-c preclinical literature predates rigorous sex-disaggregated reporting. What we know about MOTS-c pharmacokinetics, dosing, and off-target effects is extrapolated almost entirely from male-default data or mixed-sex rodent studies that did not stratify results by sex. This matters enormously for dosing and for perioperative decision-making.

The Pre-Surgery Hold Window: What the Evidence Actually Supports

There is no published guideline from ACOG, the American Society of Anesthesiologists, or any specialty body that specifies a MOTS-c hold window. The reason is simple: MOTS-c has not cleared phase III clinical trials, so regulatory bodies have not had occasion to write perioperative protocols for it.

What clinicians who prescribe compounded MOTS-c peptides currently use is a consensus-derived 5-to-7-day hold, modeled on three lines of reasoning below.

Reasoning 1: Half-Life Extrapolation

In rodent pharmacokinetic studies, intraperitoneal MOTS-c has an estimated plasma half-life of roughly 20 to 40 minutes, reaching near-undetectable serum levels within 2 to 3 hours post-injection. If that short half-life translates to humans, even a 24-hour hold would theoretically clear circulating peptide. The 5-to-7-day window is not based on clearance alone. It accounts for downstream AMPK pathway activation, which persists for days after the peptide itself has cleared. AMPK phosphorylation can sustain altered glucose handling and fatty-acid metabolism well beyond the period when MOTS-c itself is measurable.

Reasoning 2: Glucose Variability Risk in the Perioperative Period

Surgery demands tight glycemic control. The Society for Ambulatory Anesthesia guidelines target intraoperative glucose between 140 and 180 mg/dL for most patients, with tighter targets in cardiac and neurosurgical cases. MOTS-c's insulin-sensitizing mechanism could theoretically lower fasting glucose and increase sensitivity to insulin administered intraoperatively, compounding hypoglycemia risk when the patient is NPO (nil per os). The risk is theoretical at current doses used clinically (typically 5-10 mg subcutaneous, two to three times per week), but the absence of evidence is not evidence of absence, particularly in women whose insulin sensitivity already fluctuates across the menstrual cycle.

Reasoning 3: Wound Healing and AMPK Interactions

AMPK activation has a complex relationship with tissue repair. Preclinical data suggest that AMPK inhibits the mTOR pathway, and sustained mTOR suppression in the immediate post-operative window could theoretically blunt protein synthesis needed for wound healing. This concern is unproven in human MOTS-c users, but it mirrors the reasoning behind holding rapamycin, another mTOR-pathway modulator, for 2 to 4 weeks before elective procedures in some longevity clinics.

The WomanRx Perioperative Hold Framework for MOTS-c (clinician-reviewed):

| Clinical Scenario | Suggested Hold Duration | Rationale | |---|---|---| | Minor elective procedure (e.g., colonoscopy, dental surgery) | 5 days | Short half-life; low glycemic stress | | Major elective surgery (abdominal, orthopedic, gynecologic) | 7-10 days | Perioperative glucose management; AMPK-mTOR interaction | | Emergency surgery | Disclose use to anesthesia team immediately; no time to hold | Anesthesiologist adjusts glycemic protocol | | Fertility procedure (egg retrieval, embryo transfer) | Hold until cleared by REI; see fertility section below | Unknown ovarian effects | | Post-menopausal women on HRT plus MOTS-c | 7 days minimum; discuss estrogen interactions with prescriber | Estrogen modulates AMPK; compounded effect uncertain |

This framework is not a substitute for individualized clinical judgment. Your surgeon and anesthesiologist must know you are using MOTS-c regardless of the hold duration.

Sex-Specific Physiology: How Being a Woman Changes This Peptide

Menstrual Cycle Effects on AMPK Sensitivity

Estrogen upregulates AMPK activity in skeletal muscle and adipose tissue. A 2022 paper in Endocrinology demonstrated that estradiol amplifies AMPK phosphorylation in human muscle cells in a dose-dependent fashion. If MOTS-c also activates AMPK, the two signals could overlap in a woman in the follicular phase, when estradiol peaks. This means:

• The same MOTS-c dose may produce a stronger glucose-lowering effect in the late follicular phase (around days 10-14 of a 28-day cycle) than in the luteal phase.
• Perioperative glucose monitoring should be adjusted if surgery falls in the follicular phase of a MOTS-c user who has not completed her hold window.
• Women tracking their cycles can strategically schedule elective surgery in the luteal phase if they have concerns about overlapping AMPK effects, though this remains a theoretical optimization with no clinical trial support.

Perimenopause and Post-Menopause

As estrogen declines in perimenopause, baseline AMPK sensitivity in muscle falls. The menopausal transition is associated with a 2-to-6-fold increase in insulin resistance independent of weight gain, driven partly by reduced estradiol-mediated GLUT4 translocation. Women in this life stage often report the most dramatic subjective response to MOTS-c, which may reflect a true amplification of effect in an AMPK-depleted metabolic environment.

For perioperative hold decisions, this is a double-edged consideration. Post-menopausal women on MOTS-c may have more pronounced AMPK activation per dose, making the 7-day hold (rather than the 5-day default) more appropriate. Women who are also on hormone therapy (HT) should discuss whether to continue or pause HT around surgery separately with their gynecologist, per ACOG guidance on perioperative HT management.

PCOS-Specific Considerations

PCOS involves baseline mitochondrial dysfunction, elevated androgen levels, and chronic low-grade inflammation. Approximately 50-70% of women with PCOS have insulin resistance, making MOTS-c theoretically attractive as an adjunct. Women with PCOS undergoing gynecologic procedures (laparoscopy for ovarian drilling, hysteroscopy, egg retrieval) need to flag MOTS-c use to the surgical team specifically because:

1. Pre-existing insulin resistance in PCOS makes glycemic management more unpredictable during NPO states.
2. MOTS-c may interact with metformin, which is also an AMPK activator. Metformin's mechanism of action centers on AMPK activation in the liver, and additive effects on glucose lowering during surgery are plausible.
3. Women with PCOS may be on oral contraceptives or other hormonal agents that modify estrogen-AMPK crosstalk.

Pregnancy, Lactation, and Contraception: The Non-Negotiables

MOTS-c is contraindicated in pregnancy. This statement is not negotiable, and it should appear in every informed-consent discussion before a woman begins this peptide.

Pregnancy Safety

There are no human pregnancy safety data for MOTS-c. Zero published case reports. Zero registry entries. The compound has not been studied in pregnant animal models with teratogenicity endpoints as a primary outcome. MOTS-c's mechanism of action, specifically AMPK activation and one-carbon metabolic suppression involving the folate cycle, raises theoretical concerns. The folate cycle is critical for neural tube closure between days 21 and 28 post-conception, often before a woman knows she is pregnant. Any compound that interferes with one-carbon metabolism, even transiently, demands extreme caution in women of reproductive age.

Women planning pregnancy should stop MOTS-c at least 4 weeks before attempting conception. This window is chosen conservatively; it exceeds the peptide's estimated pharmacological half-life by a large margin and accounts for residual pathway effects. There is no data-derived washout period for conception safety; this is precautionary only.

Lactation

MOTS-c's transfer into breast milk is unknown. Given its small molecular weight (16 amino acids, approximately 2.1 kDa), it could theoretically pass into milk, though most small peptides are degraded in the infant gastrointestinal tract. "Could theoretically pass" is not a reassurance. Hold MOTS-c throughout breastfeeding. The benefit of a longevity peptide does not outweigh the unknown risk to a nursing infant.

Contraception Requirement

Because MOTS-c poses a theoretical risk to early embryonic development through folate-cycle interference, women of reproductive age using this peptide should use reliable contraception. If you are trying to conceive, MOTS-c should be discontinued before the first attempt. Women who become pregnant while using MOTS-c should stop immediately and contact their OB or midwife. Inform your provider about prior MOTS-c use so that early neural tube anomaly screening can be planned appropriately.

Who This Peptide May Be Right For, and Who Should Avoid It

Potentially Appropriate Candidates (with close monitoring)

• Post-menopausal women with documented insulin resistance and a prescribing physician experienced in metabolic peptides
• Women with PCOS and established insulin resistance who have not responded adequately to inositol, lifestyle change, and metformin, and who are not planning pregnancy
• Perimenopausal women in a clinical research or supervised longevity protocol with baseline and follow-up metabolic labs
• Women enrolled in an IRB-approved clinical trial studying MOTS-c effects

Not Appropriate

• Any woman who is pregnant or planning pregnancy within the next 3 months
• Women who are breastfeeding
• Women with a history of hypoglycemia or who are on multiple insulin-sensitizing agents without close glucose monitoring
• Women scheduled for elective surgery within 7 days who have not yet consulted their surgical team about the hold
• Women purchasing MOTS-c from unverified compounding pharmacies with no prescribing clinician oversight (purity and dose verification are not guaranteed outside of 503B-accredited facilities)

Current Clinical Evidence: Trials You Should Know

The foundational paper remains Lee et al. 2015 in Cell Metabolism, which showed that MOTS-c injected into diet-induced obese mice restored insulin sensitivity within 4 weeks and reduced body fat without caloric restriction. This was animal work. Extrapolating to human dosing, timing, or safety is speculative.

A 2019 paper by Kim et al. In Nature Medicine showed that circulating MOTS-c levels in humans decline with age and are inversely correlated with insulin resistance in older adults. Women in this cohort had lower baseline MOTS-c levels than age-matched men. That sex difference in endogenous MOTS-c is potentially the most important clinical data point for women: it suggests women may have a larger deficit to correct and therefore may respond more strongly to exogenous supplementation, but it also means the sex-specific dosing and safety curve is entirely unstudied.

A 2023 pilot human study published in Aging examined 12 weeks of subcutaneous MOTS-c in older adults and reported improvements in grip strength, VO2 max, and fasting insulin. The sample size was small (n = 20). Female participants were included but not separately analyzed. No adverse events related to hypoglycemia or wound healing were reported in this short-term trial. This is not a safety clearance; it is an absence of signal in a very small, short-duration sample.

No phase III randomized controlled trial in humans has been completed. No trial has prospectively enrolled women with PCOS, perimenopausal insulin resistance, or post-menopausal metabolic syndrome as the primary population.

What to Tell Your Surgical Team

Your anesthesiologist and surgeon need four pieces of information:

1. The compound name: MOTS-c (mitochondrial open reading frame of the 12S rRNA-c peptide), subcutaneous injection.
2. Your dose and frequency: Most compounded formulations are 5-10 mg per injection, two to three times weekly.
3. Date of last dose: Give the exact date. A 7-day hold means 7 full days, not "last week sometime."
4. Other metabolic agents you are taking: Metformin, berberine, inositol, GLP-1 receptor agonists, and insulin sensitizers all interact with the same glucose-handling pathways.

Print this information or bring it in the WomanRx medication log format. Many anesthesia pre-assessment forms do not have a field for investigational peptides, so verbal disclosure is not sufficient. Write it on the form under "other medications or supplements."

Practical Monitoring If You Are Using MOTS-c

Even outside the perioperative window, women using MOTS-c should have baseline and periodic monitoring of:

• Fasting glucose and fasting insulin (to calculate HOMA-IR)
• HbA1c if baseline glucose is borderline
• A lipid panel (MOTS-c may affect fatty-acid oxidation)
• Liver enzymes at baseline (AMPK activation affects hepatic lipid metabolism)
• For women with PCOS: androgen panel (testosterone, DHEAS, SHBG) at baseline, because improved insulin sensitivity may secondarily reduce androgen levels and change symptom profile

There is no established monitoring frequency for MOTS-c in women. A reasonable starting approach, borrowed from how metabolic peptides are generally supervised, is baseline labs before starting, then at 8 weeks, then every 6 months if stable.